Regeneron's Eylea and Genmab's Darzalex face biosimilar and patent expirations. An analyst with long positions sees pipeline M&A as the fix. Deadlines are tight.
The patent cliff is back as a dominant concern in biopharma. A Seeking Alpha analyst with a long position in Regeneron (REGN), Genmab (GMAB), and Apogee Therapeutics (APGE) laid out the risk: billions in annual sales could vanish as key patents expire. The industry is trying to fill the gap with pipeline assets and bolt-on acquisitions. The window is tight.
Regeneron’s Eylea, a blockbuster for wet age-related macular degeneration, faces biosimilar competition in the next few years. Genmab’s Darzalex, co-developed with Johnson & Johnson, is a multiple myeloma staple with patent expirations on the horizon. The analyst noted that both companies have early-stage pipelines but lack near-term catalysts large enough to replace the lost revenue.
The typical response has been small-scale M&A. Companies like Merck and Bristol-Myers have snapped up biotechs with mid-stage assets. The analyst said Regeneron and Genmab are likely to follow that playbook, though deal sizes remain modest. Apogee, which is developing a next-generation asthma drug, represents the kind of target that could fit.
AlphaScala’s proprietary scoring system rates REGN at 60 out of 100 – a Moderate signal – and GMAB at 69, also Moderate. Those scores reflect balanced risk versus reward. The patent cliff is priced in. The market has not fully discounted the execution risk of filling the pipeline. A delay in a key trial or a disappointing partnership could widen the gap.
The analyst’s disclosure revealed a long position in all three names. That is a bullish bet on the pipeline and deal thesis. The timeline is the hard part. Eylea biosimilar entry is expected as soon as 2025. Darzalex patents start rolling off later this decade. The bolt-on deals need to produce results before those cliffs hit.
For a trader watching REGN and GMAB, the next concrete marker is the pipeline readouts scheduled through 2025. If those data disappoint, the valuation gap between current revenue and future expectations could widen. If they hit, the discount narrows. The next 18 to 24 months will determine whether the bet pays off.
Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.